20.500.12556/DiRROS-8641 Novosti v dopolnilnem zdravljenju HER2-pozitivnega raka dojke Update on Adjuvant Treatment of HER2-Positive Breast Cancer Although trastuzumab-based regimens have improved both systemic control and overall survival in the patients with HER2-positive breast cancer, in some of these patients, tumor progression occurs despite trastuzumab treatment. New target therapies are searched for these patients. The most promising and, in terms of clinical use, the most developed is lapatinib, a small molecule, tyrosine-kinase inhibitor that targets not only HER2- but also HER1-receptor. It is already used for treating the HER2-positive metastatic breast cancer patients after failure of trastuzumab therapy, but its effectiveness in adjuvant therapy has not been proven yet. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization) is a randomized phase-three multi-center study of adjuvant lapatinib, trastuzumab, their sequence and their combination in the patients with HER2 positive primary breast cancer. true false true Slovenski jezik Angleški jezik by Authors Neznano 2018-08-31 13:27:20 2018-08-31 13:27:20 2022-08-16 10:09:54 0000-00-00 00:00:00 2008 0 0 str. 57-60 št. 1 Letn. 12 jun. 2008 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 1408-1741 URN:NBN:SI:doc-BRZ6IBU5 620411 65324032 RAZ_Matos_Erika_i2008.pdf RAZ_Matos_Erika_i2008.pdf 1 D3B1F1E8647C3D7CAC0CAEA4FF977FBF 905636819c2ec56e0015d7c7a53b4b01f6d9489b5e5630b702a4515877fcbc12 5496aae0-17b5-11ed-b6b8-001a4af901a5 20.500.12556/dirros/16586f5e-b9b6-451a-8d0c-d282b6692bec https://dirros.openscience.si/Dokument.php?lang=slv&id=10422 Onkološki inštitut Ljubljana Onkologija : strokovni časopis za zdravnike 0 0 0